A meta-analysis of therapy comparison between bimatoprost and timolol in ocular hypertention eye

Chinese Ophthalmic Research

Volumn 27, Issue 12, 2009, Pages 1120-1125

  Ge, Yirui ^a   Wang, Lili ^a   Cheng, Jinwei ^a   Huang, Zhenping ^a  

^a NANJING GENERAL HOSPITAL OF NANJING MILITARY COMMAND   (China)

Author keywords

Bimatoprost; Evidence based medicine; High intraocular pressure; Meta analysis; Timolol

Indexed keywords

BIMATOPROST; TIMOLOL;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COCHRANE LIBRARY; CONJUNCTIVAL HYPEREMIA; DATA BASE; DRUG EFFECT; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MEDLINE; META ANALYSIS; REFERENCE DATABASE; SYSTEMATIC REVIEW; THERAPY EFFECT;

EID: 75149124407     PISSN: 10030808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Thylefors BI. The WHO program for the prevention of blindness [J]. Ophthalmic Epidemiol, 1994,1:3-4
2. Chinese source
3. Owen CG, Carey IM , de Wilde S. The epidemiology of medical treatment for glaucoma and ocular hypertension in the United Kingdom: 1994 to 2003 [J]. Br J Ophthalmol, 2006,90:861-868
4. Li N, Chen XM, Zhou Y, et al. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials [J]. Clin Exp Ophthalmol, 2006,34:755-764
5. Cheng JW, Wei RL. Meta-analysis of 13 randomized controlled trials comparing bimatoprost with latanoprost in patients with elevated intraocular pressure [J]. Clin Ther, 2008,30:622-632
6. Denis P, Lafuma A, Khoshnood B, et al. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy [J]. Curr Med Res Opin, 2007,23:601-608
7. Chinese source
8. Stewart WC. Perspectives in the medical treatment of glaucoma [J]. Curr Opin Ophthalmol, 1999,10:99-108
9. Schweitzer I, Maguire K, Ng CH. A case of melancholic depression induced by beta-blocker antiglaucoma agents [J]. Med J Aust, 2008,189:406-407
10. Diggory P, Cassels-Brown A, Vail A, et al. Avoiding unsuspected respiratory side-effects of topical timolol with cardioselective or sympathomimetic agents [J]. Lancet, 1995,345:1604-1606
11. Chinese source
12. Chinese source
13. Martin E, Martinez-de-la-Casa JM, Garcia-Feijoo J, et al. A 6-month assessment of bimatoprost 0.03% vs timolol maleate 0.5%: hypotensive efficacy, macular thickness and flare in ocular-hypertensive and glaucoma patients [J]. Eye, 2007,21:164-168
14. Higginbotham EJ, Schuman JS, Goldberg I, et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension [J]. Arch Ophthalmol, 2002,120:1286-1293
15. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [M]. Chichester; John Wiley & Sons Inc., 2005:115
16. Williams RD, Cohen JS, Gross RL. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4 [J]. Br J Ophthalmol, 2008,92:1387-1392
17. Brandt JD, Cantor LB, Katz LJ, et al. Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension [J]. J Glaucoma, 2008,17:211-216
18. Oztürk F, Yavas GF, Küsbeci T, et al. The effect of ocular hypotensive agents on macula [J]. Ann Ophthalmol (Skokie), 2007,39:302-306
19. Martinez A, Sanchez MA. Comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open-angle glaucoma[J]. Curr Med Res Opin, 2007,23:1025-1032
20. Rossetti L, Karabatsas CH, Topouzis F, et al. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure [J]. Ophthalmology, 2007,114:2244-2251
21. Hommer A, Ganfort Investigators Group I. A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension [J]. Eur J Ophthalmol, 2007,17:53-62
22. Ozturk F, Ermis SS, Inan UU. Comparison of the ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6-month study [J]. Acta Ophthalmol Scand, 2007,85:80-83
23. Brittain CJ, Saxena R, Waldock A. Prospective comparative switch study from timolol 0.5% and latanoprost 0.005% to bimatoprost 0.03% [J]. Adv Ther, 2006,2:68-73
24. Day DG, Sharpe ED, Beischel CJ, et al. Safety and efficacy of bimatoprost 0.03% versus timolol maleate 0.5%/dorzolamide 2% fixed combination [J]. Eur J Ophthalmol, 2005,15:336-342
25. Manni G, Centofanti M, Parravano M, et al. A 6-month randomized clinical trial of bimatoprost 0.03% versus the association of timolol 0.5% and latanoprost 0.005% in glaucomatous patients [J]. Graefe's Arch Clin Exp Ophthalmol, 2004,242:767-770
26. Cohen JS, Gross RL, Cheetham JK, et al. Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension [J]. Surv Ophthalmol, 2004,49(1):S45-52
27. Walters TR, DuBiner HB, Carpenter SP, et al. 24-hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial [J]. Surv Ophthalmol, 2004,49:S26-35
28. Coleman AL, Lerner F, Bernstein P, et al. A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension [J]. Ophthalmology, 2003,110:2362-2368
29. Netland PA, Michael M, Rosner SA, et al. Brimonidine purite and bimatoprost compared with timolol and latanoprost in patients with glaucoma and ocular hypertension [J]. Adv Ther, 2003,20:20-30
30. Whitcup SM, Cantor LB, van Denburgh AM , et al. A randomised, double masked,multicentre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma and ocular hypertension [J]. Br J Ophthalmol, 2003,87:57-62
31. Laibovitz RA, van Denburgh AM, Felix C, et al. Comparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy, and safety evaluation of a novel compound for glaucoma management [J]. Arch Ophthalmol, 2001,119:994-1000
32. Sherwood M, Brandt J, Bimatoprost Study Groups 1 and 2. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure [J]. Surv Ophthalmol, 2001,45:S361-368
33. Brandt JD, van Denburgh AM, Chen K, et al. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial [J]. Ophthalmology, 2001,108:1023-1031
34. Chinese source
35. Brubaker RF, Schoff EO, Nau CB. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics [J]. Am J Ophthalmol, 2001,131:19-24
36. Yu AL, Fuchshofer R, Kampik A, et al. A Effect of oxidative stress in trabecular meshwork cells are reduced by prostaglandin analogues [J]. Invest Ophthalmol Vis Sci, 2008,49:4872-4880
37. van der Valk R, Webers CA, Schouten JS, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs; a meta-analysis of randomized clinical trials [J]. Ophthalmology, 2005,112:1177-1185
38. The AGIS Investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration [J]. Am J Ophthalmol, 2000,130:429-440
39. Yeom HY, Hong S, Kim SS, et al. Influence of topical bimatoprost on macular thickness and volume in glaucoma patients with phakic eyes [J]. Can J Ophthalmol, 2008,43:563-566
40. Chinese source
41. Goldberg LD, Walt J. Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications [J]. Pharmacoeconomics, 2006,24:251-264
42. Holmstrom S, Buchholz P, Walt J. The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries [J]. Curr Med Res Opin, 2006,22:897-905